Remove Medical Schools Remove Protein Production Remove Research
article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

Engineering of Chinese hamster ovary cell lipid metabolism results in an expanded ER and enhanced recombinant biotherapeutic protein production. He has a post-doctorate in virology, viral pathogenesis, viral vector development, and vaccines evaluation from Harvard Medical School and a PhD in Virology/Molecular Biology.

article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

In addition, machine learning can potentially provide predictive models to assist in reducing process gaps and enhance productivity. Disclaimer: For research use only. Engineering of Chinese hamster ovary cell lipid metabolism results in an expanded ER and enhanced recombinant biotherapeutic protein production.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

The Pharma Data

25, 2021 /PRNewswire/ — Elasmogen Ltd , the pioneering biopharmaceutical company leading the development of VNAR and soloMER biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially capable of stopping COVID-19 infections. ABERDEEN, Scotland , Jan.

article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

December 5, 2:00 PM – 3:30 PM; Platform A: Translational Research / Genetics. Translational Research / 2B. December 8, 1:30 PM – 4:00 PM; Annual Fundamentals Symposium: Fundamentally New Ideas in Epilepsy Treatment and Research. December 6, 12:00 PM – 1:30 PM; Track: 2. Devices, Technologies, Stem Cells. Lori Isom, Ph.D.,